Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2014

Intangible Assets

Schedule of intangible assets

	September 30, 2014
(In thousands)	Weighted Average Remaining Amortization Period (Years)	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
FDA approval and launch of BREO® ELLIPTA® in the U.S.	16.0	$	60,000	$	(3,411	)	$	56,589
Minister of Health, Labor and Welfare (“MHLW”) approval and launch of RELVAR® ELLIPTA® in Japan	14.2	20,000		(1,111		)	18,889
European Commission approval and launch of RELVAR® ELLIPTA®	14.3	30,000		(1,500		)	28,500
FDA approval and launch of ANORO® ELLIPTA® in the U.S.	16.0	60,000		(1,565		)	58,435
European Commission approval and launch of ANORO® ELLIPTA®	14.9	30,000		(656		)	29,344
MHLW approval and launch of ANORO® ELLIPTA®  in Japan	15.0	20,000		(111		)	19,889
Total intangible assets		$	220,000	$	(8,354	)	$	211,646

	December 31, 2013
(In thousands)	Weighted Average Remaining Amortization Period (Years)	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
FDA approval and launch of BREO® ELLIPTA® in the U.S.	15.7	$	60,000	$	(632	)	$	59,368
MHLW approval and launch of RELVAR® ELLIPTA® in Japan	14.9	20,000		(111		)	19,889
European Commission approval of RELVAR® ELLIPTA®	15.0	15,000		—			15,000
FDA approval of ANORO® ELLIPTA® in the U.S.	15.2	30,000		—			30,000
Total intangible assets		$	125,000	$	(743	)	$	124,257